Lantheus
LNTH
100.18
+0.23
+0.23%
Lantheus
US · LNTH
#1847 by market cap
Listed 2015
100.18
+0.23
+0.23%
Live - 5344 symbols - heartbeat 264s ago
· 2026-10-08 01:17
After-hours
99.90
-0.28%
Overnight
100.98
+0.80%
- Market cap
- 6.54B
- P/E (TTM)i
- 23.97
- P/Bi
- 4.99
- EPSi
- 3.41
- Div yieldi
- 0.00%
- 52W posi
- 81%
Reader sentiment
Are you bullish or bearish on LNTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.34, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.50% YoY
Margins
- Gross margin
- 61.10%
- Operating margin
- 20.47%
- Net margin
- 15.15%
Key ratios & quality
- Enterprise valuei
- 6.75B
- PEG ratioi
- 0.23
- Altman Z-Scorei
- 5.34
PEG uses trailing P/E against the 3-year net income growth rate (102.64%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 343.37M | 347.34M | 339.41M | 425.21M | 935.06M | 1.30B | 1.53B | 1.54B |
| Gross profit | 174.89M | 174.81M | 138.76M | 187.70M | 581.70M | 709.54M | 988.29M | 941.95M |
| Selling & admin expenses | 93.33M | 103.13M | 110.17M | 218.82M | 233.83M | 267.19M | 371.63M | 453.81M |
| Research & development | 17.07M | 20.02M | 32.79M | 44.97M | 311.68M | 77.71M | 168.10M | 177.31M |
| Operating profit | 64.49M | 51.66M | -4.20M | -76.09M | 36.20M | 364.64M | 448.56M | 315.56M |
| Pretax profit | 49.55M | 28.63M | -11.48M | -75.04M | 26.72M | 410.94M | 430.98M | 313.79M |
| Tax | 9.03M | -3.04M | 1.99M | -3.76M | -1.35M | 84.28M | 118.54M | 80.23M |
| Net profit | 40.52M | 31.67M | -13.47M | -71.28M | 28.07M | 326.66M | 312.44M | 233.56M |
| Basic EPS | 1 | 1 | 0 | -1 | 0 | 5 | 5 | 3 |
| Diluted EPS | 1.03 | 0.79 | -0.25 | -1.06 | 0.40 | 4.65 | 4.36 | 3.41 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 372.76M | 378.05M | 384.01M | 406.79M | 377.33M | 388.18M |
| Gross profit | 237.70M | 241.01M | 222.37M | 240.88M | 230.92M | 241.86M |
| Selling & admin expenses | 99.32M | 107.56M | 130.73M | 116.21M | 110.22M | 103.44M |
| Research & development | 36.31M | 45.49M | 48.03M | 47.48M | 39.38M | 38.20M |
| Operating profit | 106.79M | 87.97M | 43.62M | 77.18M | 81.33M | 100.22M |
| Pretax profit | 96.53M | 104.52M | 42.38M | 70.37M | 156.41M | 93.83M |
| Tax | 23.58M | 25.76M | 14.61M | 16.28M | 37.99M | 18.80M |
| Net profit | 72.95M | 78.76M | 27.77M | 54.09M | 118.42M | 75.03M |
| Basic EPS | 1 | 1 | 0 | 1 | 2 | 1 |
| Diluted EPS | 1.02 | 1.12 | 0.41 | 0.82 | 1.80 | 1.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 195.42M | 172.91M | 184.23M | 235.79M | 677.62M | 1.09B | 1.33B | 899.96M |
| Cash & ST investments | 113.40M | 92.92M | 79.61M | 98.51M | 415.65M | 713.66M | 912.81M | 359.12M |
| Inventory | 33.02M | 29.18M | 35.74M | 35.13M | 35.48M | 64.03M | 68.03M | 64.67M |
| Total assets | 439.83M | 405.92M | 869.82M | 863.78M | 1.32B | 1.65B | 1.98B | 2.23B |
| Total current liabilities | 52.76M | 66.11M | 80.50M | 90.50M | 247.70M | 187.35M | 240.53M | 333.42M |
| Short-term debt | 2.75M | 10.14M | 20.70M | 11.64M | 354.00K | 823.00K | 974.00K | 738.00K |
| Long-term debt | 263.71M | 183.93M | 197.70M | 163.12M | 557.71M | 561.67M | 565.28M | 568.68M |
| Total liabilities | 368,829,000.00 | 291,318,000.00 | 355,616,000.00 | 399,345,000.00 | 874,111,000.00 | 835,257,000.00 | 892,329,000.00 | 1,137,602,000.00 |
| Total equity | 71.00M | 114.60M | 514.21M | 464.44M | 447.15M | 815.89M | 1.09B | 1.09B |
| Retained earnings | -168.14M | -136.47M | -149.95M | -221.23M | -193.16M | 133.50M | 445.95M | 679.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.42B | 1.20B | 925.09M | 899.96M | 942.29M | 1.03B |
| Cash & ST investments | 938.53M | 695.57M | 382.01M | 359.12M | 498.58M | 593.30M |
| Inventory | 69.13M | 62.16M | 62.04M | 64.67M | 61.34M | 57.55M |
| Total assets | 2.06B | 2.12B | 2.28B | 2.23B | 2.35B | 2.41B |
| Total current liabilities | 248.00M | 280.13M | 346.84M | 333.42M | 333.17M | 335.68M |
| Short-term debt | 747.00K | 796.00K | 871.00K | 738.00K | 803.00K | 697.00K |
| Long-term debt | 566.10M | 566.85M | 567.94M | 568.68M | 569.60M | 570.35M |
| Total liabilities | 891,030,000.00 | 949,294,000.00 | 1,157,194,000.00 | 1,137,602,000.00 | 1,134,299,000.00 | 1,102,884,000.00 |
| Total equity | 1.16B | 1.17B | 1.12B | 1.09B | 1.21B | 1.31B |
| Retained earnings | 518.89M | 597.65M | 625.42M | 679.50M | 797.92M | 872.95M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 61.19M | 80.38M | 16.40M | 53.92M | 281.78M | 305.26M | 544.75M | 390.14M |
| Depreciation & amortization | 13.93M | 13.38M | 24.69M | 42.29M | 47.93M | 60.04M | 64.62M | 70.10M |
| Free cash flow | 41.06M | 58.32M | 3.92M | 41.78M | 263.43M | 258.71M | 465.13M | 348.64M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 428.00K | 573.00K | 683.00K | 767.00K | -73.63M | 1.93M | -96.55M | -296.29M |
| Ending cash balance | 113.40M | 92.92M | 82.69M | 100.65M | 417.24M | 715.29M | 914.49M | 360.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 107.56M | 87.11M | 105.29M | 90.18M | 125.13M | 92.20M |
| Depreciation & amortization | 13.63M | 13.23M | 20.41M | 22.83M | 22.68M | 22.58M |
| Free cash flow | 98.85M | 73.73M | 94.67M | 81.39M | 121.90M | 89.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.98M | -101.98M | -96.27M | -100.02M | 0 | 0 |
| Ending cash balance | 940.21M | 697.26M | 383.70M | 360.83M | 500.29M | 595.02M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 85.94 | 34.12 | -4.29 | -14.57 | 6.16 | 51.73 | 32.82 | 21.45 |
| ROA %i | 9.84 | 7.49 | -2.11 | -8.22 | 2.57 | 21.98 | 17.21 | 11.10 |
| ROIC %i | 17.41 | 12.72 | -1.29 | -9.21 | 3.73 | 26.54 | 19.11 | 13.51 |
| 5-year avg ROE %i | -- | -- | -- | -- | 21.47 | 14.63 | 14.37 | 19.52 |
| EBIT margin %i | 19.50 | 12.16 | -0.59 | -15.82 | 3.63 | 33.24 | 29.38 | 21.64 |
| FCF / sales %i | 11.96 | 16.79 | 1.16 | 9.82 | 28.17 | 19.96 | 30.32 | 22.62 |
| Current ratioi | 3.70 | 2.62 | 2.29 | 2.61 | 2.74 | 5.80 | 5.52 | 2.70 |
| Quick ratioi | 2.98 | 2.06 | 1.66 | 2.08 | 2.54 | 5.33 | 5.16 | 2.20 |
| Debt / assetsi | 60.58 | 47.81 | 27.12 | 22.15 | 44.16 | 37.36 | 31.28 | 27.81 |
| LT debt / equityi | 371.41 | 160.49 | 41.85 | 38.68 | 130.42 | 75.52 | 56.84 | 56.77 |
| Interest coveragei | 3.85 | 3.10 | -0.21 | -8.68 | 4.72 | 21.53 | 22.91 | 16.89 |
| Revenue CAGR (3Y) %i | 5.38 | 4.79 | 0.80 | 7.39 | 39.11 | 56.32 | 53.37 | 18.13 |
| Net income CAGR (3Y) %i | -- | 5.77 | -- | -- | -3.94 | -- | -- | 102.64 |
| FCF CAGR (3Y) %i | 68.32 | 11.35 | -52.77 | 0.58 | 65.30 | 304.05 | 123.30 | 9.79 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 24.11 | 24.71 | 14.59 | 21.45 | 23.48 | 22.21 |
| ROA %i | 13.09 | 13.36 | 7.75 | 11.10 | 12.68 | 12.15 |
| ROIC %i | 14.45 | 15.13 | 9.08 | 13.51 | 15.47 | 14.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 24.46 | 26.04 | 17.19 | 21.64 | 25.45 | 24.60 |
| FCF / sales %i | 28.96 | 31.12 | 24.94 | 22.62 | 24.04 | 24.92 |
| Current ratioi | 5.74 | 4.29 | 2.67 | 2.70 | 2.83 | 3.06 |
| Quick ratioi | 5.19 | 3.68 | 2.21 | 2.20 | 2.57 | 2.82 |
| Debt / assetsi | 29.89 | 29.09 | 27.21 | 27.81 | 26.67 | 25.88 |
| LT debt / equityi | 52.71 | 52.68 | 55.27 | 56.77 | 51.55 | 47.59 |
| Interest coveragei | 19.16 | 20.14 | 13.31 | 16.89 | 19.86 | 19.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- PYLARIFY is the largest reported line at 61.92% of revenue, across 4 reported segments.
- DEFINITY follows at 22.74%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
PYLARIFY61.92%
DEFINITY22.74%
Neuraceq10.21%
Strategic partnerships and other revenue5.13%
Quote time 2026-10-08 01:17:57 · For reference only, not investment advice and not tailored to your situation.